Professor Sattar is a clinically active academic, researching the causes, prevention and management of diabetes, obesity and CVD. He has published over 1,000 papers, and contributed to several European guidelines. He is currently involved in several lifestyle and drug trials in diabetes and CVD and leads on biomarker initiatives in other trials. He has been the recipient of multiple award lectures, including the prestigious Camillo Golgi Prize from EASD in 2020. He is a Web of Science global Highly Cited Researcher, in the top 1% for citations in their academic field since 2014.

Professor Sattar makes the following disclosures:  I declare that I have sources of funding and relationships with the following commercial stakeholders in the healthcare sector: consulting for Afimmune; Amgen; AstraZeneca; Boehringer Ingelheim; Eli Lilly; Hanmi Pharmaceuticals; Merck Sharp & Dohme; Novartis; Novo Nordisk; Pfizer; Sanofi

Grant Support paid to his University from:  AstraZeneca; Boehringer Ingelheim; Novartis; Roche Diagnostics